Receptor tyrosine kinase inhibitor tivozanib regulates cell state plasticity and restores MITF dependency in BRAF wild-type melanoma

Scientists evaluated TT-012 and found that most BRAF^WT melanoma lines were resistant to TT-012 due to low microphthalmia transcription factor (MITF) transcriptional activity and reduced dependency on MITF for proliferation.